Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice
Savitha Subramanian(University of Washington), Alan Chait(University of Washington), George N. Ioannou(VA Puget Sound Health Care System), Jin Kyu Kim(University of Washington), Kevin D. O’Brien(University of Washington), Leela Goodspeed(University of Washington), Matthew M. Yeh(University of Washington), Subramaniam Pennathur(University of Michigan), Kris V. Kowdley(Liver Institute Northwest), Lixia Zeng(University of Michigan–Ann Arbor), W. Geoffrey Haigh(University of Washington), Shari Wang(University of Washington)
Cited by 242
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k